Purpose Patients receiving platinum-based chemotherapy are in patients with lung cancer receiving platinum-based chemo- at high risk of chemotherapy-induced nausea and vomiting therapy, across the acute, delayed, and overall phases and (CINV), a distressing side effect of treatment. This post-hoc throughout multiple cycles. As a highly effective oral combi- subgroup analysis of two pivotal trials evaluated the efficacy nation antiemetic agent administered as a single dose once per of NEPA in preventing CINV in subsets of patients with lung cycle, NEPA may offer a convenient, simplified prophylactic cancer who received cisplatin or carboplatin. antiemetic. Methods In each study, the efficacy endpoints complete re- . . . sponse (CR; defined as no emetic episodes and no rescue Keywords Lung cancer Cisplatin Carboplatin medication) and no significant nausea (NSN; defined as a Chemotherapy-induced nausea and vomiting (CINV) NEPA score of < 25 mm on a visual analog scale of 0–100 mm) during the acute (0–24 h), delayed (25–120 h), and overall (0–120 h) phases post-chemotherapy in cycle 1 (study 1) Introduction and cycles 1–4 (study 2) were assessed. Safety was evaluated by recording treatment-emergent adverse events (AEs) and Lung cancer is the most common cancer worldwide, with treatment-related AEs. an estimated
Supportive Care in Cancer – Springer Journals
Published: Oct 28, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud